<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00793923</url>
  </required_header>
  <id_info>
    <org_study_id>Lucedex</org_study_id>
    <nct_id>NCT00793923</nct_id>
  </id_info>
  <brief_title>A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Wet AMD</brief_title>
  <acronym>Lucedex</acronym>
  <official_title>A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Wet Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Subhransu K. Ray, M.D., Ph.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bay Area Retina Associates</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bay Area Retina Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this proposed research study is to evaluate the safety of&#xD;
      intravitreal ranibizumab in combination with intravitreal dexamethasone in comparison to&#xD;
      intravitreal ranibizumab alone in the treatment of wet ARMD. The addition of the broad&#xD;
      spectrum anti-inflammatory activity of dexamethasone may augment the anti-VEGF activity of&#xD;
      ranibizumab by amelioration of inflammation existing in the microenvironment of the choroidal&#xD;
      neovascularization. While the anti-VEGF agents have proven to be very efficacious in the&#xD;
      treatment of exudative ARMD, their narrow target and window of activity may limit their&#xD;
      overall durability of action.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, single masked comparative trial using either combination therapy (group 1):&#xD;
      same day combination therapy with 0.05cc intravitreal dexamethasone injection (10mg/ml vial)&#xD;
      and a single 0.5 mg intravitreal ranibizumab injection for four consecutive months will be&#xD;
      compared to monotherapy (group 2): one intravitreal injection of 0.5 mg ranibizumab also&#xD;
      given for four consecutive months. These treatments will then be followed by PRN treatment&#xD;
      based on clinical exam, angiographic studies, and OCT evidence of residual subretinal fluid,&#xD;
      CME, subretinal hemorrhage, or pigment epithelial detachment. Fluorescein angiography and&#xD;
      fundus photography will be performed at baseline and at the 1, 3, 6, and 12 month follow-up&#xD;
      visits. Only OCT testing will be performed at all follow-up visits. Both groups will be&#xD;
      re-evaluated for safety at 12 and 24 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of ocular adverse events and visual acuity</measure>
    <time_frame>6 months and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total number of treatments required</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Exudative Age-Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy (group 1): same day combination therapy with 0.05cc dose intravitreal dexamethasone injection (10mg/ml vial) and a single 0.5 mg intravitreal ranibizumab injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravitreal injection of 0.5 mg ranibizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab and dexamethasone</intervention_name>
    <description>Combination therapy (group 1): same day combination therapy with 0.05cc dose intravitreal dexamethasone injection (10mg/ml vial) and a single 0.5 mg intravitreal ranibizumab injection</description>
    <arm_group_label>Combination Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>intravitreal injection of 0.5 mg ranibizumab</description>
    <arm_group_label>Monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        â€¢ Best Corrected Visual Acuity at 4 meters using ETDRS Charts between 20/32 and 20/400&#xD;
        (Snellen Equivalent) in the study eye with evidence of neovascular ARMD.&#xD;
&#xD;
        (Only one eye will be eligible for study. If both eyes are eligible, the one with the&#xD;
        better visual acuity will be selected for treatment unless, based on medical reasons, the&#xD;
        investigator deems the other eye to be more appropriate for treatment and study.)&#xD;
&#xD;
          -  All lesion subtypes will be enrolled with the following criteria Predominantly and&#xD;
             minimally classic: Angiographic lesion greater than 50% of the total lesion area&#xD;
             Occult: Lesions must show recent activity progression with respect to vision,&#xD;
             subretinal hemorrhage or subretinal fluid&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Age greater than or equal to 50 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment for ARMD in the study eye&#xD;
&#xD;
          -  Previous intravitreal drug delivery in the study eye&#xD;
&#xD;
          -  Previous vitrectomy in the study eye&#xD;
&#xD;
          -  Fibrosis or atrophy involving the center of the fovea in the study eye&#xD;
&#xD;
          -  Neovascular membrane from any other concurrent retinal disease such as high myopia&#xD;
             (SER &gt; -8D), histoplasmosis or other ocular inflammatory disease.&#xD;
&#xD;
          -  Known history of glaucoma and on more than one topical medication&#xD;
&#xD;
          -  History of glaucoma filtering surgery in the study eye&#xD;
&#xD;
          -  History of corneal transplant in the study eye&#xD;
&#xD;
          -  Patients with active co-existing macular disease such as diabetic macular edema&#xD;
&#xD;
          -  Active intraocular inflammation in the study eye&#xD;
&#xD;
          -  History of allergy to fluorescein not amenable to treatment&#xD;
&#xD;
          -  Pregnancy (positive pregnancy test) or lactation&#xD;
&#xD;
          -  Premenopausal women not using adequate contraception. The following are considered&#xD;
             effective means of contraception: surgical sterilization or use of oral&#xD;
             contraceptives, barrier contraception with either a condom or diaphragm in conjunction&#xD;
             with spermicidal gel, an IUD, or contraceptive hormone implant or patch.&#xD;
&#xD;
          -  Any other condition that the investigator believes would pose a significant hazard to&#xD;
             the subject if the investigational therapy were initiated&#xD;
&#xD;
          -  Inability to comply with study or follow up procedures&#xD;
&#xD;
          -  Participation in another simultaneous medical investigation or trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Subhransu K Ray, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bay Area Retina Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bay Area Retina Associates</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>November 17, 2008</study_first_submitted>
  <study_first_submitted_qc>November 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2008</study_first_posted>
  <last_update_submitted>December 18, 2012</last_update_submitted>
  <last_update_submitted_qc>December 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Bay Area Retina Associates</investigator_affiliation>
    <investigator_full_name>Subhransu K. Ray, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Exudative Age Related Macular Degeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

